Northwestern Mutual Wealth Management
TSHA icon

Northwestern Mutual Wealth Management’s Taysha Gene Therapies TSHA Stock Holding History

Northwestern Mutual Wealth Management’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-8
Closed -$44 – 4465
2025
Q4 		$44 Buy
+8
New +$39 ﹤0.01% 3910
2023
Q2 		– Sell
-10,000
Closed -$7.98K – 3615
2023
Q1 		$7.98K Hold
10,000
– – ﹤0.01% 2583
2022
Q4 		$22.6K Buy
+10,000
New +$20.2K ﹤0.01% 2211

Other funds holding TSHA

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Northwestern Mutual Wealth Management's TSHA Position: Q1 2026 in Review

Northwestern Mutual Wealth Management sold out of Taysha Gene Therapies (TSHA) in Q1 2026, closing a stake of 8 shares — an estimated $44 sold.

Northwestern Mutual Wealth Management first reported a position in TSHA in Q4 2022 and held it in 3 quarters. The position peaked at $22.6K in Q4 2022. 191 funds tracked by Wall St. Rank hold TSHA as of Q1 2026.

  • Northwestern Mutual Wealth Management reported no remaining Taysha Gene Therapies position as of Q1 2026 after selling out during the quarter.
  • Northwestern Mutual Wealth Management sold 8 Taysha Gene Therapies shares in Q1 2026, an estimated $44.
  • Northwestern Mutual Wealth Management first reported a position in Taysha Gene Therapies in Q4 2022 and held it in 3 quarters.
  • Northwestern Mutual Wealth Management's Taysha Gene Therapies position peaked at $22.6K in Q4 2022.
  • 191 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q1 2026.

Based on Northwestern Mutual Wealth Management's 13F filing for Q1 2026, filed 7 May 2026.